Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical 07/11/2022 — Expected to
July 11, 2022
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical 07/11/2022 — Expected to
Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study VANCOUVER, British Columbia, July
Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate VANCOUVER, British
Cybin Acquires DMT Clinical Study from Entheon Biomedical 06/07/2022 — Acquisition of largest Phase 1
UNITy: World’s first study of how DMT-induced brain changes predict improved wellbeing University College London
Psychedelic Fauna for Psychonaut Hunters: A Mini-Review We bet you never knew that these animals
Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation
Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT
Delic Labs Receives Health Canada 56 Exemption to Conduct Research on MDMA, LSD and Other
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT Cybin (CYBN) found
Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules
PharmaDrug Advances DMT-Analogue Program for Glaucoma with Production of Medical Device Designed to Provide Sustained
Biomind Labs Opens a New Clinical Psychedelic Research Facility March 17, 2022 07:25 AM Eastern
Small Pharma Expands Potential of Commercial Portfolio with DMT-based Psychedelic Assets After finding its DMT
Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research Numinus (NUMI) received Health
Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules Robust Portfolio of Psychedelic-Inspired Molecules
World’s First clinical trial for DMT-assisted therapy in Major Depressive Disorder Shows Consistent Quality of
PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma Glaucoma can cause irreversible vision
World’s First clinical trial for DMT-assisted therapy in Major Depressive Disorder Shows Consistent Quality of
New study offers a detailed glimpse into the otherworldly encounters produced by the psychedelic drug
Core One Labs Expects Imminent Breakthrough to Produce NMT, Precursor to DMT Vancouver, British Columbia,
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the
Entheon Biomedical Announces the Approval of DMT Clinical Trial Entheon Biomedical (ENBI) received approval for a
Did you know that one of the most promising addiction treatments is a psychedelic compound